Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

In Vitro Pharmacodynamic Analyses Help Guide the Treatment of Multidrug-Resistant Enterococcus faecium and Carbapenem-Resistant Enterobacter cloacae Bacteremia in a Liver Transplant Patient.

Wenzler E, Santarossa M, Meyer KA, Harrington AT, Reid GE, Clark NM, Albarillo FS, Bulman ZP.

Open Forum Infect Dis. 2020 Jan 4;7(1):ofz545. doi: 10.1093/ofid/ofz545. eCollection 2020 Jan.

2.

Activity of imipenem-relebactam and meropenem-vaborbactam against carbapenem-resistant SME-producing Serratia marcescens.

Biagi M, Shajee A, Vialichka A, Jurkovic M, Tan X, Wenzler E.

Antimicrob Agents Chemother. 2020 Jan 13. pii: AAC.02255-19. doi: 10.1128/AAC.02255-19. [Epub ahead of print]

PMID:
31932381
3.

Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis.

Borjan J, Meyer KA, Shields RK, Wenzler E.

Int J Antimicrob Agents. 2020 Jan;55(1):105852. doi: 10.1016/j.ijantimicag.2019.11.009. Epub 2019 Nov 23.

PMID:
31770627
4.

Ex Vivo Urinary Bactericidal Activity and Urinary Pharmacodynamics of Fosfomycin after Two Repeated Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Subjects.

Wenzler E, Meyer KM, Bleasdale SC, Sikka M, Mendes RE, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA.

Antimicrob Agents Chemother. 2020 Jan 27;64(2). pii: e02102-19. doi: 10.1128/AAC.02102-19. Print 2020 Jan 27.

PMID:
31767717
5.

Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.

Biagi M, Tan X, Wu T, Jurkovic M, Vialichka A, Meyer K, Mendes RE, Wenzler E.

J Clin Microbiol. 2020 Jan 28;58(2). pii: e01603-19. doi: 10.1128/JCM.01603-19. Print 2020 Jan 28.

PMID:
31748318
6.

Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat.

Butler DA, Biagi M, Tan X, Qasmieh S, Bulman ZP, Wenzler E.

Curr Infect Dis Rep. 2019 Nov 16;21(12):46. doi: 10.1007/s11908-019-0706-5. Review.

PMID:
31734740
7.

BundlED Up: A Narrative Review of Antimicrobial Stewardship Initiatives and Bundles in the Emergency Department.

Santarossa M, Kilber EN, Wenzler E, Albarillo FS, Sterk EJ.

Pharmacy (Basel). 2019 Nov 1;7(4). pii: E145. doi: 10.3390/pharmacy7040145. Review.

8.

Association Between Estimated Pharmacokinetic/Pharmacodynamic Predictions of Efficacy and Observed Clinical Outcomes in Obese and Nonobese Patients With Enterobacteriaceae Bloodstream Infections.

Santibañez M, Bunnell K, Harrington A, Bleasdale S, Wenzler E.

Open Forum Infect Dis. 2019 Sep 19;6(10):ofz400. doi: 10.1093/ofid/ofz400. eCollection 2019 Oct.

9.

AUC-Based Monitoring of Vancomycin: Closing the Therapeutic Window.

Biagi MJ, Butler DA, Wenzler E.

J Appl Lab Med. 2019 Jan;3(4):743-746. doi: 10.1373/jalm.2018.027391. No abstract available.

10.
11.

Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam.

Biagi M, Wu T, Lee M, Patel S, Butler D, Wenzler E.

Antimicrob Agents Chemother. 2019 Sep 30. pii: AAC.01426-19. doi: 10.1128/AAC.01426-19. [Epub ahead of print]

PMID:
31570403
12.

Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy.

Biagi M, Butler D, Tan X, Qasmieh S, Tejani K, Patel S, Rivosecchi RM, Nguyen MH, Clancy CJ, Shields RK, Wenzler E.

Antimicrob Agents Chemother. 2019 Sep 16. pii: AAC.01085-19. doi: 10.1128/AAC.01085-19. [Epub ahead of print]

PMID:
31527035
13.

A randomized, open-label pharmacokinetic trial of tacrolimus extended-release dosing in obese de novo kidney transplant recipients.

Jasiak-Panek NM, Wenzler E, Patel S, Thielke JJ, Progar K, Patel S, Brandt S, Huang YJ, Benedetti E, West-Thielke PM.

Clin Transplant. 2019 Aug;33(8):e13640. doi: 10.1111/ctr.13640. Epub 2019 Jul 1.

PMID:
31206808
14.

Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model.

Meyer KA, Deraedt MF, Harrington AT, Danziger LH, Wenzler E.

Int J Antimicrob Agents. 2019 Aug;54(2):197-201. doi: 10.1016/j.ijantimicag.2019.04.010. Epub 2019 Apr 26.

PMID:
31034937
15.

A Breath of Fresh Air in the Fog of Antimicrobial Resistance: Inhaled Polymyxins for Gram-Negative Pneumonia.

Biagi M, Butler D, Tan X, Qasmieh S, Wenzler E.

Antibiotics (Basel). 2019 Mar 16;8(1). pii: E27. doi: 10.3390/antibiotics8010027. Review.

16.

In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.

Wu T, Meyer K, Harrington AT, Danziger LH, Wenzler E.

J Antimicrob Chemother. 2019 May 1;74(5):1300-1305. doi: 10.1093/jac/dkz010.

PMID:
30753495
17.

Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms.

Wenzler E, Lee M, Wu TJ, Meyer KA, Shields RK, Nguyen MH, Clancy CJ, Humphries RM, Harrington AT.

J Antimicrob Chemother. 2019 Mar 1;74(3):633-638. doi: 10.1093/jac/dky483.

18.

Implementation and optimization of molecular rapid diagnostic tests for bloodstream infections.

Wenzler E, Timbrook TT, Wong JR, Hurst JM, MacVane SH.

Am J Health Syst Pharm. 2018 Aug 15;75(16):1191-1202. doi: 10.2146/ajhp170604. Epub 2018 Jul 3. Review.

PMID:
29970407
19.

Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants.

Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA; Antibacterial Resistance Leadership Group.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00464-18. doi: 10.1128/AAC.00464-18. Print 2018 Aug.

20.

Impact of Clinical and Laboratory Standards Institute breakpoint changes on susceptibility rates of cephalosporins in uncomplicated urinary tract infections caused by Enterobacteriaceae.

Bunnell KL, Wenzler E, Harrington AT, Danziger LH.

Diagn Microbiol Infect Dis. 2018 Apr;90(4):335-336. doi: 10.1016/j.diagmicrobio.2017.12.007. Epub 2017 Dec 16.

PMID:
29395714
21.

Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects.

Bunnell KL, Pai MP, Sikka M, Bleasdale SC, Wenzler E, Danziger LH, Rodvold KA.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02475-17. doi: 10.1128/AAC.02475-17. Print 2018 Apr.

22.

Clinical use of the polymyxins: the tale of the fox and the cat.

Wenzler E, Bunnell KL, Danziger LH.

Int J Antimicrob Agents. 2018 May;51(5):700-706. doi: 10.1016/j.ijantimicag.2017.12.023. Epub 2018 Jan 3.

PMID:
29305954
23.

Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile.

Guinta MM, Bunnell K, Harrington A, Bleasdale S, Danziger L, Wenzler E.

Ann Clin Microbiol Antimicrob. 2017 Dec 4;16(1):77. doi: 10.1186/s12941-017-0252-7.

24.

Reply to Dilworth et al.

Wenzler E, Wang F, Goff DA, Prier B, Mellett J, Mangino JE, Bauer KA.

Clin Infect Dis. 2017 Nov 13;65(11):1957-1958. doi: 10.1093/cid/cix677. No abstract available.

PMID:
29020165
25.

Impact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infection.

Bauer KA, Johnston JEW, Wenzler E, Goff DA, Cook CH, Balada-Llasat JM, Pancholi P, Mangino JE.

Anaerobe. 2017 Dec;48:1-6. doi: 10.1016/j.anaerobe.2017.06.009. Epub 2017 Jun 21.

PMID:
28645479
26.

Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.

Wenzler E, Ellis-Grosse EJ, Rodvold KA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00775-17. doi: 10.1128/AAC.00775-17. Print 2017 Sep.

27.

Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.

Wenzler E, Deraedt MF, Harrington AT, Danizger LH.

Diagn Microbiol Infect Dis. 2017 Aug;88(4):352-354. doi: 10.1016/j.diagmicrobio.2017.05.009. Epub 2017 May 18.

PMID:
28602518
28.

Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.

Meyer K, Santarossa M, Danziger LH, Wenzler E.

Hosp Pharm. 2017 Mar;52(3):221-228. doi: 10.1310/hpj5203-221.

29.

Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration.

Wenzler E, Bunnell KL, Bleasdale SC, Benken S, Danziger LH, Rodvold KA.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00464-17. doi: 10.1128/AAC.00464-17. Print 2017 Jul.

30.

An Automated, Pharmacist-Driven Initiative Improves Quality of Care for Staphylococcus aureus Bacteremia.

Wenzler E, Wang F, Goff DA, Prier B, Mellett J, Mangino JE, Bauer KA.

Clin Infect Dis. 2017 Jul 15;65(2):194-200. doi: 10.1093/cid/cix315.

PMID:
28379326
31.

Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.

Wenzler E, Goff DA, Humphries R, Goldstein EJC.

Infect Dis Ther. 2017 Jun;6(2):149-172. doi: 10.1007/s40121-017-0149-y. Epub 2017 Mar 4. Review.

32.

Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Wenzler E, Fraidenburg DR, Scardina T, Danziger LH.

Clin Microbiol Rev. 2016 Jul;29(3):581-632. doi: 10.1128/CMR.00101-15. Review.

33.

Controversies in Antimicrobial Stewardship: Focus on New Rapid Diagnostic Technologies and Antimicrobials.

Wenzler E, Wong JR, Goff DA, Jankowski CA, Bauer KA.

Antibiotics (Basel). 2016 Jan 14;5(1). pii: E6. doi: 10.3390/antibiotics5010006.

34.

Urinary Tract Infections: Resistance Is Futile.

Wenzler E, Danziger LH.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2596-7. doi: 10.1128/AAC.00006-16. Print 2016 Apr. No abstract available.

35.

Impact of rapid identification of Acinetobacter Baumannii via matrix-assisted laser desorption ionization time-of-flight mass spectrometry combined with antimicrobial stewardship in patients with pneumonia and/or bacteremia.

Wenzler E, Goff DA, Mangino JE, Reed EE, Wehr A, Bauer KA.

Diagn Microbiol Infect Dis. 2016 Jan;84(1):63-68. doi: 10.1016/j.diagmicrobio.2015.09.018. Epub 2015 Sep 30.

PMID:
26603136
36.

Clinical and microbiological outcomes in patients with Streptococcus anginosus group bacteraemia identified through use of a rapid microarray assay.

Wenzler E, Chandrasekaran V, Salvador P, Anwar M, Pancholi P, McGwire BS.

J Med Microbiol. 2015 Nov;64(11):1369-74. doi: 10.1099/jmm.0.000176. Epub 2015 Sep 25.

PMID:
26408191
37.

Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.

Wenzler E, Gotfried MH, Loutit JS, Durso S, Griffith DC, Dudley MN, Rodvold KA.

Antimicrob Agents Chemother. 2015 Dec;59(12):7232-9. doi: 10.1128/AAC.01713-15. Epub 2015 Sep 8.

38.

Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.

Wenzler E, Rodvold KA.

Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S38-47. doi: 10.1093/cid/civ522. Review.

PMID:
26316557
39.

Hepatitis C Management and the Infectious Diseases Pharmacist.

Wenzler E, Dickson W, Vibhakar S, Adeyemi OM, Danziger LH.

Clin Infect Dis. 2015 Oct 1;61(7):1201-2. doi: 10.1093/cid/civ545. Epub 2015 Jul 1. No abstract available.

PMID:
26136390
40.

Severe Sepsis Secondary to Persistent Lysinibacillus sphaericus, Lysinibacillus fusiformis and Paenibacillus amylolyticus Bacteremia.

Wenzler E, Kamboj K, Balada-Llasat JM.

Int J Infect Dis. 2015 Jun;35:93-5. doi: 10.1016/j.ijid.2015.04.016. Epub 2015 Apr 27.

41.

Editorial commentary: improving prescribers to advance antimicrobial stewardship.

Wenzler E, Rodvold KA, Danziger LH.

Clin Infect Dis. 2015 Apr 15;60(8):1259-61. doi: 10.1093/cid/civ021. Epub 2015 Jan 16. No abstract available.

PMID:
25595751
42.

The Antimicrobial Stewardship Approach to Combating Clostridium Difficile.

Wenzler E, Mulugeta SG, Danziger LH.

Antibiotics (Basel). 2015 Jun 17;4(2):198-215. doi: 10.3390/antibiotics4020198. Review.

43.

Hyperhomocysteinemia in retinal artery and retinal vein occlusion.

Wenzler EM, Rademakers AJ, Boers GH, Cruysberg JR, Webers CA, Deutman AF.

Am J Ophthalmol. 1993 Feb 15;115(2):162-7.

PMID:
8430725
44.

[Report from Man, Ivory Coast].

Wenzler E.

Dtsch Schwesternztg. 1968 Sep;21(9):447-9. German. No abstract available.

PMID:
4300249

Supplemental Content

Loading ...
Support Center